生物製药发酵市场－全球产业规模、份额、趋势、机会、预测：按产品类型、应用、最终用户、地区和竞争格局划分，2021-2031年

全球生物製药发酵市场预计将从 2025 年的 251.1 亿美元成长到 2031 年的 409.9 亿美元，复合年增长率为 8.51%。

在这个领域，生物反应器利用细菌、酵母和哺乳动物细胞等生物系统生产单株抗体和疫苗等治疗药物。推动该领域发展的主要因素是全球慢性病盛行率的上升以及对生物治疗方法日益增长的需求。此外，重磅药物专利到期加速了生物相似药的研发，从而持续推高了生产能力。欧洲製药工业协会联合会（EFPIA）估计，到2024年，欧洲製药业在研发方面的投资将达到550亿欧元，这凸显了这些生产需求所获得的巨额资金支持。

市场成长的主要障碍在于建造和验证符合cGMP标准的设施所需的大量资本支出。将发酵製程从实验室规模放大到商业化生产的技术难题也构成了重要的进入门槛。这种财务和技术负担常常限制了小规模生产商快速扩大产能的能力，可能导致供应链瓶颈，并阻碍新疗法进入商业市场的速度。

市场驱动因素

生物製药研发投入的增加是发酵市场发展的重要驱动力。随着企业积极研发新型生物製药，这笔不断增长的投资支持了对单株抗体和重组蛋白等复杂分子的研究，因为先进的发酵技术对于这些分子的开发和商业化至关重要。资金的增加使製造商能够优化上游工程程式参数并提高产量，从而确保有前景的候选疗法能够顺利地从实验室规模过渡到工业生物反应器。根据美国製药製造商协会 (PhRMA) 于 2024 年 4 月发布的《2024 年 PhRMA 年度会员调查》，会员公司在 2023 年的研发投入高达 1035 亿美元，这表明大量资金正涌入，支持发酵衍生疗法的创新研发。

将生产外包给合约研发生产机构（CDMO）的趋势日益增长，这透过缓解创新者面临的产能限制，进一步扩大了市场规模。随着符合cGMP规范的发酵技术标准日益严格，製药研发公司正利用CDMO的专业基础设施来降低资本风险并缩短产品上市时间。三星生物製剂在2024年1月公布的2023年第四季及全年财务业绩中，其合併年销售额达到3.69兆韩元，凸显了市场对外包服务的强劲需求。为了满足全球对生物製药日益增长的需求，主要企业也努力提升自身的生产能力。例如，诺和诺德承诺在2024年投资41亿美元，在北卡罗来纳州新建一座生产设施，旨在提高注射剂的产量。

市场挑战

建立和验证符合cGMP规范的设施需要巨额资本投入，这是全球生物製药发酵市场面临的主要障碍。这笔高额资金门槛主要限制了市场准入，只有资金雄厚的大型製药公司才能进入，实际上将无力承担巨额前期投资的中小型製造商和Start-Ups排除在外。因此，生产能力高度集中，供应链的韧性和柔软性受到影响。此外，发酵製程从实验室规模放大到商业规模的技术难题也加剧了这个问题。製程偏差和验证失败可能造成巨大损失，并可能延迟关键治疗药物的上市。

这些经济限制因素直接阻碍了产能扩张以满足日益增长的全球需求。将一种药物推向市场的相关成本，包括实施严格的生产控制，清楚地表明了产品成功所需的巨额投资。根据国际药品製造商协会联合会（IFPMA）估计，到2024年，开发一种新药的平均成本将达到26亿美元。如此庞大的成本结构迫使企业在为新设施分配资金时格外谨慎，导致基础设施瓶颈，阻碍了发酵市场的进一步扩张。

市场趋势

随着相关人员越来越重视环境管理，向永续和环保生物製造方法的转变正在改变商业运作。製造商正在逐步淘汰再生能源来源，并优化用水，以实现供应链脱碳并达成雄心勃勃的净零排放目标。这项策略转变旨在降低长期营运成本，同时满足工业排放的监管要求。例如，在2025年12月发表于《医疗保健数字》（Healthcare Digital）的一篇题为“安进如何将拯救生命的生物技术与永续性相结合”的报导中，安进宣布将于2025年投资9亿美元扩建其位于俄亥俄州的工厂，这将是该公司首个全电动製造地，以支持其碳中和目标。

同时，人工智慧数位双胞胎技术的整合正在革新市场上的规模化生产和生命週期管理。借助先进的演算法，製造商可以即时模拟发酵过程，预测影响效力的各种变量，而无需进行大量的物理实验。这种数位化变革有助于预测性维护，减少批次失败，并大幅加快研发进度。为了支持这项技术进步，赛诺菲在2025年9月发布的新闻稿中宣布增加对技术支援的投入，以推动其人工智慧驱动的生物製药策略。新闻稿题为「赛诺菲向赛诺菲创投追加投资6.25亿美元，加速生物技术和数位健康领域的创新投资」。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球生物製药发酵市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品类型（上游工程产品、下游製程产品）
  • 依应用领域（抗生素、重组蛋白等）
  • 按最终用户划分（生物製药产业、受託研究机构、学术研究机构、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美生物製药发酵市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲生物製药发酵市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区生物製药发酵市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲生物製药发酵市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲生物製药发酵市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球生物製药发酵市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Agilent Technologies, Inc.
• Eppendorf SE
• Thermo Fisher Scientific Inc.
• c-LEcta GmbH
• Sartorius AG
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Nova Biomedical Corporation
• Concord Biotech Limited
• Solaris Biotechnolgy Srl

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Biopharmaceutical Fermentation Market is projected to expand from USD 25.11 Billion in 2025 to USD 40.99 Billion by 2031, reflecting a CAGR of 8.51%. This sector utilizes biological systems, including bacteria, yeast, or mammalian cells, within bioreactors to produce therapeutic agents such as monoclonal antibodies and vaccines. Growth is primarily fuelled by the increasing prevalence of chronic diseases worldwide and the growing necessity for biologic treatments. Additionally, the patent expiration of key blockbuster medications is hastening the development of biosimilars, creating a continuous requirement for enhanced manufacturing capabilities. Highlighting the substantial financial backing for these production needs, the European Federation of Pharmaceutical Industries and Associations estimated that the industry invested 55,000 million Euros in research and development across Europe in 2024.

A major obstacle hindering market growth is the immense capital expenditure needed to build and validate facilities that comply with cGMP standards. The technical difficulties involved in scaling fermentation processes from laboratory settings to commercial manufacturing establish significant entry barriers. This financial and technical strain frequently restricts smaller manufacturers' ability to rapidly increase capacity, which can lead to supply chain bottlenecks and impede the pace at which new therapeutic products reach the commercial market.

Market Driver

Increasing R&D spending in biopharmaceutical discovery is a fundamental driver of the fermentation market, as companies aggressively seek to develop novel biologics. This rise in financial investment supports the investigation of complex molecules, such as monoclonal antibodies and recombinant proteins, which depend heavily on sophisticated fermentation methods for development and commercialization. Enhanced funding enables manufacturers to refine upstream bioprocessing parameters and boost yields, ensuring that promising therapeutic candidates can successfully transition from laboratory scales to industrial bioreactors. According to the Pharmaceutical Research and Manufacturers of America (PhRMA) '2024 PhRMA Annual Membership Survey' released in April 2024, member companies invested $103.5 billion in research and development during 2023, representing a massive capital influx that sustains the innovation pipeline for fermentation-derived therapeutics.

The growing trend of outsourcing production to Contract Development and Manufacturing Organizations (CDMOs) is further broadening market scope by relieving capacity limitations for innovators. As the technical standards for cGMP-compliant fermentation tighten, pharmaceutical developers are utilizing the specialized infrastructure of CDMOs to reduce capital risks and hasten time-to-market. Samsung Biologics highlighted this robust demand for outsourced services in its 'Fourth Quarter and Annual 2023 Financial Results' from January 2024, reporting a consolidated annual revenue of KRW 3.69 trillion. To satisfy the rising global demand for biologic supplies, major industry players are also strengthening their internal capacities; for instance, Novo Nordisk committed to a $4.1 billion investment in 2024 to build a new manufacturing facility in North Carolina, specifically aimed at increasing the production of injectable treatments.

Market Challenge

The substantial capital expenditure necessary to establish and validate cGMP-compliant facilities represents a major hurdle for the Global Biopharmaceutical Fermentation Market. This high financial threshold restricts market entry largely to major, well-funded pharmaceutical companies, effectively excluding smaller manufacturers and startups that cannot afford such significant upfront investments. As a result, manufacturing capacity remains concentrated, diminishing the resilience and flexibility of the supply chain. The technical difficulties associated with scaling fermentation processes from lab benchmarks to commercial volumes further intensify this issue, as the costs related to process deviations or validation failures can be prohibitive, potentially delaying the rollout of critical therapeutics.

These economic constraints directly limit the rate at which the industry can broaden its production capabilities to satisfy rising global demand. The sheer scale of investment required for successful product launches is underscored by the expenses involved in bringing a drug to market, which includes implementing strict manufacturing controls. According to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the average cost to develop a new medicine was estimated at USD 2.6 billion in 2024. This massive cost structure compels companies to allocate capital for new facilities with extreme caution, resulting in infrastructure bottlenecks that impede the broader expansion of the fermentation market.

Market Trends

The move towards Sustainable and Green Bio-Manufacturing Practices is transforming operations as stakeholders place a higher priority on environmental stewardship. Manufacturers are progressively adopting renewable energy sources and optimizing water usage to decarbonize supply chains and achieve ambitious net-zero goals. This strategic shift is designed to lower long-term operational expenses while satisfying regulatory demands concerning industrial emissions. For instance, according to a December 2025 article by Healthcare Digital titled 'How Amgen Combines Life-Saving Biotech & Sustainability', Amgen announced a US$900 million expansion for its Ohio facility in 2025, which is intended to be its first fully electric biomanufacturing site in support of carbon neutrality objectives.

Simultaneously, the integration of AI and Digital Twins for Process Optimization is revolutionizing scale-up and lifecycle management within the market. By utilizing advanced algorithms, manufacturers are able to simulate fermentation processes in real-time, allowing them to predict variables impacting titer without the need for extensive physical experimentation. This digital evolution facilitates predictive maintenance, decreases batch failures, and notably hastens development schedules. To back this technological advancement, Sanofi announced in a September 2025 press release titled 'Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation' that it has increased funding to support technologies that drive its AI-powered biopharmaceutical strategy.

Key Market Players

• Agilent Technologies, Inc.
• Eppendorf SE
• Thermo Fisher Scientific Inc.
• c-LEcta GmbH
• Sartorius AG
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Nova Biomedical Corporation
• Concord Biotech Limited
• Solaris Biotechnolgy Srl

Report Scope

In this report, the Global Biopharmaceutical Fermentation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biopharmaceutical Fermentation Market, By Product Type

• Upstream Products
• Downstream Products

Biopharmaceutical Fermentation Market, By Application

• Antibiotics
• Recombinant Proteins
• Others

Biopharmaceutical Fermentation Market, By End User

• Biopharmaceutical Industries
• Contract Research Organization
• Academic Research Institutes
• Others

Biopharmaceutical Fermentation Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biopharmaceutical Fermentation Market.

Available Customizations:

Global Biopharmaceutical Fermentation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biopharmaceutical Fermentation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Upstream Products, Downstream Products)
  • 5.2.2. By Application (Antibiotics, Recombinant Proteins, Others)
  • 5.2.3. By End User (Biopharmaceutical Industries, Contract Research Organization, Academic Research Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Biopharmaceutical Fermentation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Biopharmaceutical Fermentation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Biopharmaceutical Fermentation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Biopharmaceutical Fermentation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Biopharmaceutical Fermentation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Biopharmaceutical Fermentation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Biopharmaceutical Fermentation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Biopharmaceutical Fermentation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Biopharmaceutical Fermentation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Biopharmaceutical Fermentation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Biopharmaceutical Fermentation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Biopharmaceutical Fermentation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Biopharmaceutical Fermentation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Biopharmaceutical Fermentation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Biopharmaceutical Fermentation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Biopharmaceutical Fermentation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Biopharmaceutical Fermentation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Biopharmaceutical Fermentation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Biopharmaceutical Fermentation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Biopharmaceutical Fermentation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Biopharmaceutical Fermentation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Biopharmaceutical Fermentation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Biopharmaceutical Fermentation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Biopharmaceutical Fermentation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Biopharmaceutical Fermentation Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Eppendorf SE
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. c-LEcta GmbH
• 15.5. Sartorius AG
• 15.6. Danaher Corporation
• 15.7. F. Hoffmann-La Roche Ltd.
• 15.8. Nova Biomedical Corporation
• 15.9. Concord Biotech Limited
• 15.10. Solaris Biotechnolgy Srl

16. Strategic Recommendations

17. About Us & Disclaimer